IMMUNITYBIO, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $45.0K | $44.0K | $236.0K | $641.0K | $600.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $42.0M | $29.2M | $11.4M | $1.6M | $446.0K |
| SG&A Expense | $57.1M | $95.4M | $227.7M | $4.6M | $2.4M |
| Operating Income | $-99.1M | $-124.5M | $-238.9M | $-5.6M | — |
| Operating Margin | -220,266.7% | -282,954.5% | -101,218.6% | -869.7% | — |
| Interest Expense | $618.0K | $66.0K | $0 | $471.0K | $463.0K |
| Pretax Income | $-96.9M | $-121.4M | $-237.2M | $-6.2M | — |
| Income Tax Expense | $-493.0K | $-572.0K | $-301.0K | $1.0K | $1.0K |
| Net Income | $-96.4M | $-120.8M | $-236.9M | $-6.2M | $-2.0M |
| Net Margin | -214,273.3% | -274,565.9% | -100,371.2% | -964.9% | -341.2% |
| EPS (Basic) | $-1.20 | $-1.47 | $-3.31 | $-0.75 | $-2.57 |
| EPS (Diluted) | $-1.20 | $-1.47 | $-3.31 | $-0.75 | $-2.57 |
| Shares Outstanding (Basic) | 79.0M | 82.0M | 81.3M | — | — |
| Shares Outstanding (Diluted) | 79.0M | 82.0M | 81.3M | — | — |
| Dividends Per Share | — | — | — | — | — |